Perrigo Company plc Research and Development Asset Acquired Other than Through Business Combination, Written-off
Perrigo Company plc (PRGO) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $6.00 million for the 12-month period ending 2014-06-28, per its 10-K filed 2014-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2015-08-13
- Perrigo Company plc research and development asset acquired other than through business combination, written-off for the quarter ending 2013-12-28 was $6.00M.
- Perrigo Company plc research and development asset acquired other than through business combination, written-off for fiscal 2014 was $6.00M, a 33.33% decline from fiscal 2013.
- Perrigo Company plc research and development asset acquired other than through business combination, written-off for fiscal 2013 was $9.00M.
- Perrigo Company plc research and development asset acquired other than through business combination, written-off for fiscal 2012 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|
| 2014-06-28 | $6.00M 10-K · filed 2014-08-14 | |
| 2013-12-28 | $6.00M 10-K · filed 2015-08-13 | |
| 2013-06-29 | $9.00M 10-K · filed 2014-08-14 | |
| 2012-06-30 | $0.00 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |